Anna Rita Migliaccio, PhD, University of Bologna, Bologna, Italy, discusses novel insights into the pathogenesis of myelofibrosis and the changes involved in the development of myeloproliferative neoplasms from benign forms of disease. Dr Migliaccio outlines the use of ruxolitinib, which improves symptoms of myelofibrosis but highlights the need for curative therapies, including treatments targeting TGF-beta and p-selectin which have shown in mouse models to have curative effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).